Novo Nordisk to outsource peptide API synthesis to contract manufacturers
Macquarie calls the Capital Markets Day disclosure a break from Novo's vertically integrated model, which had limited partners to fill-finish, packaging and device assembly.
TR
By Tom Reyes · Markets Editor
Oct 5 04:20 ETSource: Moneycontrol.com
The wire
- 01At its Capital Markets Day Novo Nordisk said it will use contract manufacturers for peptide API synthesis while continuing to expand internal capacity, a shift Macquarie says is driven by oral formulation demand.
- 02Macquarie estimates moving from injectable Wegovy to an oral formulation raises annual API needs per patient roughly 73-fold, as Novo targets growth in oral Wegovy patients from 1.5 million to 15 million by 2030.
- 03The note flags WuXi AppTec, Divi's Laboratories and Samsung Biologics as candidates, but no contracts were announced and Macquarie says cost, quality and existing Eli Lilly relationships will shape selection.
From the source
Read at moneycontrol.comNovo's manufacturing pivot reinforces peptide CDMO case; Divi's is Macquarie's top Indian pick
Novo Nordisk's plan to use contract manufacturers for peptide API production reinforces the investment case for peptide CDMOs, Macquarie said in a note. Manufacturing cost is likely to shape which partners Novo picks.
